

A - a a a a -a a
a a a a a a - - a COVID-19. T
P -A C V F a T a .

F a A. Ca a ^{1,2}, A G ³, Ca G. Wa ⁴, J M C ³

¹ A a a H U , D E a M a ,
D a M , E a Pa a M a, U a F a S
Pa (EPM/UNIFESP), S Pa , SP, B a

² C a I , B a a, DF, B a

³ A B I , I , CA, USA

⁴ B U , RI, USA

A :
F a A. Ca a , MD, MS , P D
D E a M a , D a M ,
E a Pa a M a, U a F a S Pa
R a P T 781 13 , 04039-032 S Pa , SP B a
E a : [a . a a @ .](mailto:a.a.a@.) ; [. a a @ a .](mailto:.a.a@.)
T : +55 61 996506111, Fa : +55 61 33464733

K - : COVID-19, SARS-C V-2, a a , a , a ,

A a

Ba : W COVID-19 a a a a a ,
a a a a a a , a a a
a a a a a a a a a COVID-19. A
a a a a a , a (HA) ,
a (PCOS), a , a a a a a
(CAH) a a a a (AGA), a HA a a
a a a . T a a a
a a a a a a a a a COVID-19

a , a a HA a a a

a a .

Ma a a : F a a a

COVID-19 a - a a a (PCR-SARS-C V-2)

a a a -HA, HA, a HA a (HA-)

. Pa a a a , 23 a , 44

a a a , 28 , a a a

a COVID-19 a a . T a a ,

a 500 / a a a a , a a

400 / a a , a a 500 a a a ,

0.2 / / a a , a a a 100 a a .

Pa a COVID-19 a , a a a a , a

a .

R : I a , 270 a , 195, 67, a -HA, HA,

a HA- , . P a a a (71.1%), a a

(67.0%), a a (48.1%), a a (37.4%), (36.3%), a a

a (34.1%), a (33.3%), a (29.5%), a (27.8%), a a

(24.8%), a a (24.1%) a (21.5%). Ea (a)

(1.0 ± 0.2 day), abdominal pain (1.1 ± 0.3); a a (1.1 ± 0.5),

a a a (1.2 ± 0.5), a a (1.2 ± 0.5), dry cough (1.2 ± 0.5),

a a (1.2 ± 0.4), a a (1.3 ± 0.5) a a (1.3 ± 0.5). T - - a ,

PCR, a a a a a a a a

a HA- a -HA, HA, a a - . T - - a

a a a a a PCR-SARS-C V-2

a -HA a HA. S a

a a a - COVID-19. F -HA a HA a

a a a a a , a , a a a. A a ,

a a a a a -HA a HA. N a

a a a COVID-19 a .

C : A , a COVID-19 a a a a

a a a a a

-, a -, a (BMI)-, a a - a - a

a , a a a - a a a

a a COVID-19 a . HA a
a a a , a
. S a a a HA.

Background

COVID-19 a - a - a a S
A R a S C a 2 (SARS-C V-2). I a a
a a a a , a a a a ,
a a a (1-4).

O a a a a
a a a a a a a , a
COVID-19 a , a a a
a a a a , a a a a a
a a a a .

W a a a a a a
a a a a , a a a a a a
a a COVID-19, a a
a a a , . . , COVID-19 a a
. M a . a a a a
a a a a a , a
(5).

B a a - a , a a ,
a a a , a a a a ,
a a a , a .

Y a a a a
, a a a , a a a a

(a a a a a a a a a a),
a a , a a
a a a COVID-19
a a a a a (6-9).

A a a a
sine-quo-non a a a -
P a C a R a (PCR) SARS-C V-2 (10,11). W
a COVID-19,
COVID-19 a , a a COVID-19 a a
a a a . T a a a
a a COVID-19 a a a a
a COVID-19, *per se* a a a a
COVID-19 a a . R a a COVID-
19 a a a a 10%
a (12-14).

S a a *in vitro* a a a a SARS-
C V-2 a a a a COVID-19 (13), a
a a a a a ,
a a , a a (13,14). H ,
COVID-19 a a a a
, a a a a , a a
a a a . A , a a a
(RCT) a a COVID-19 , a a a
a a (10-14).

W a a a a a a a a
COVID-19 a a ,
a a a a a a . T a a a
a a a , a COVID-19 a a
a a a , a a a a .

A , a , a a
a COVID-19 a a a , a a ,
a / a (15-23). O a a
a a COVID-19 a a ,
a (BMI), a , *i.e.*, a a
a (15-18). T a , a a a , a a
a 2 (TMPRSS-2), a a SARS-C V-2 , a
a a a a a . A a , a a a
(AGA) a a a a COVID-19,
a a a (AR), a
(DHT) , a , a a
a , a AGA a a a .

W a a a COVID-19 a ,
a a , a , a 2 a (T2DM),
a a COVID-19 a
a a . I a , a a a a a AGA a , a
a a (HA), a
(PCOS), a , a a a a (CAH) 21a a-
a 11 a- a , a AGA, a HA, a
a a a a a a
a a -HA a .

I a , a a a a , a
a a a a a , a a a (19-22). T
a a a a a a a
COVID-19. N , a a a a ,
a a a , a a a .

T a , a a , a a a
a a a a a
COVID-19 a a a a , a
a , a a a a a

.A , a a a ,
.

T , a a , a a
a , a a a
a a a .

T a a a
a a a a COVID-19 a
a - a , a a a a
a . I a , a - a a a 0 a a
- a a a

A a , A , USA; C a SARS-C V-2, R , S a), a SARS-C V-2 .

I a : 1. C COVID-19 PCR-SARS-C V-2; 2. 18 a a a ; 3. L a a ; 4. L a 72 COVID-19 a (a COVID-19 a a a); 4. N a 24 a a a ; a 5. N a a .

Design and methods

Pa a a a a Ta 1. F a a a a , 23 a , 44 a a a , 28 , a a HA, : 1. PCOS R a C a; 2. P a CAH; 3. K a , a - a ; 4. H ; a 5. F a AGA. F a a HA (-HA), a a a , a 100 / a a (HA-S) (HA).

C a a 1. A a- A a a ; 2. D - a / a a ; 3. U a a (URTI) URTI- a / a a ; 4. Ga a (GI) - a / a a ; 5. M ; 6. U a ; 7. A a .

T a a , a : 1. A a-A a a : a a a a , , - , - a ; 2. D - a a : a a a a, a a a , a a - a a ; 3. URTI- a a : a a a a , , - , - a ;

4. GI - a a : a a a a, a a , ,
a a a ;

5. M : a a a

6. U a : a

a a ;

7. A a .

A a a a , a a 500 / a
a , 400 / a a , a a 500
a a a , 0.2 / / a a a . T
, a a , a / a a a
a - a a , . . , a , a
. I a , a , a D, a C, , a a a ,
a a a , a a , a a , a a
a .

Pa a a : 1. T - -a a a a a
(a); 2. T ,
a a a a (a); 3. T ,
a a a a (a); 4. D a PCR-SARS-
C V-2 (a , PCR a a); 5. L
a Da -7 -4, -3 -1, 0, 1, 2, 3, 7, 14, 21, 30 a 60 a ,
0 a (a a
) a 100 a a a ; 6. A
a a Da 0, 3, 7, 14 a 30 (0 = a a a 100 =
a a - a a a); 7. WHO COVID O a
O S a ; 8. B a COVID-19 ; 9. D a ,
a a , a a a , a a . F a a a a a a a a
(:// . / 4 8/).

Statistical analysis

ANOVA (Kruskal-Wallis) test was used to compare the baseline characteristics of the two groups. A *post-hoc* analysis was performed using the Dunn-Sidak test, with $p < 0.05$. All analyses were performed using XLSTAT (Mouscron, Belgium), (USA).

Aspect	Parameter
Baseline characteristics	<p>! "#\$%&'()*! +,-./:;<=>?@A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [\] ^ _ ` { } ~ ¡ ¢ £ ¤ ¥ ¦ § ¨ © ª « ¬ ® ¯ ° ± ² ³ ´ µ ¶ · ¸ ¹ º » ¼ ½ ¾ ¿ À Á Â Ã Ä Å Æ Ç È É Ê Ë Ì Í Î Ï Ñ Ò Ó Ô Õ Ö × Ø Ù Ú Û Ü Ý Þ ß à á â ã ä å æ ç è é ê ë ì í î ï ð ñ ò ó ô õ ö ÷ ø ù ú û ü ý þ ÿ</p>
Disease and treatment timing	<p>! "#\$%&'()*! +,-./:;<=>?@A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [\] ^ _ ` { } ~ ¡ ¢ £ ¤ ¥ ¦ § ¨ © ª « ¬ ® ¯ ° ± ² ³ ´ µ ¶ · ¸ ¹ º » ¼ ½ ¾ ¿ À Á Â Ã Ä Å Æ Ç È É Ê Ë Ì Í Î Ï Ñ Ò Ó Ô Õ Ö × Ø Ù Ú Û Ü Ý Þ ß à á â ã ä å æ ç è é ê ë ì í î ï ð ñ ò ó ô õ ö ÷ ø ù ú û ü ý þ ÿ</p>
Medical history	<p>! "#\$%&'()*! +,-./:;<=>?@A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [\] ^ _ ` { } ~ ¡ ¢ £ ¤ ¥ ¦ § ¨ © ª « ¬ ® ¯ ° ± ² ³ ´ µ ¶ · ¸ ¹ º » ¼ ½ ¾ ¿ À Á Â Ã Ä Å Æ Ç È É Ê Ë Ì Í Î Ï Ñ Ò Ó Ô Õ Ö × Ø Ù Ú Û Ü Ý Þ ß à á â ã ä å æ ç è é ê ë ì í î ï ð ñ ò ó ô õ ö ÷ ø ù ú û ü ý þ ÿ</p>
Current medications	<p>! "#\$%&'()*! +,-./:;<=>?@A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [\] ^ _ ` { } ~ ¡ ¢ £ ¤ ¥ ¦ § ¨ © ª « ¬ ® ¯ ° ± ² ³ ´ µ ¶ · ¸ ¹ º » ¼ ½ ¾ ¿ À Á Â Ã Ä Å Æ Ç È É Ê Ë Ì Í Î Ï Ñ Ò Ó Ô Õ Ö × Ø Ù Ú Û Ü Ý Þ ß à á â ã ä å æ ç è é ê ë ì í î ï ð ñ ò ó ô õ ö ÷ ø ù ú û ü ý þ ÿ</p>

Ca	a	a	<p>1 \$-4<>:(B. \$5!!</p> <p>" 8#+(-\$87+8!B(8=\$5-\$5!+8, +>+-(57!% " EP+)!%<A5+:)!</p> <p>" 8#+(-\$87+8<1!5\$B\$A-(5!>:(B. \$57!% " F 1)!%<-48)!</p> <p>J ((A!6+95\$-+B7!%@95(7\$ 0+6\$)!!</p> <p>; ,+4Q+6\$!6+95\$-+B7!%, &65(B, :(5(+4Q+6\$!% / E ; R)!+864A4 0+6\$)! </p> <p>E4:B+9 0 !B, 488\$!:>:(B. \$57!%EE 1)!%<6+A+8\$)! </p> <p>M<7A45+8#!6+95\$-+B7!%7A+5(8(:4B-(8\$)! </p> <p>G-4+87!%A+4=4<5(79=4<5!4-(5=4<5!A54=4<5!7+0=47-4+8)! </p> <p>L-, \$5!:+A+6<:(? \$5+8#!4#\$8-7!%@+>54-\$7\$!\$Q\$+0+>\$!DEGMT!</p> <p>+8, +>+-(57)! </p> <p>" 7A+5+8!</p> <p>E:(A+6(#5\$:! </p> <p>* 45@45+8!</p> <p>U4!@4B-(5!+8, +>+-(57!%4A+>4048\$!5+=45(04>48)! </p> <p>C+5\$B!-, 5(0>+8!+8, +>+-(57!%64>4#4-548)! </p> <p>/ \$A45+87!</p> <p>!</p>
D	a	, a	<p>1 +#948+6\$7!% 0 \$-@ (50+8)! </p> <p>V:9B4#(8<+:. \$!A\$A-+6\$!W!%V J DW)!5\$B\$A-(5!484:(#9\$7!%V J D<</p> <p>WF4)!%:+54<5!7\$ 0 4<5!69:4#:9+6\$X!\$0\$84+6\$)! </p> <p>G(6+9 0 <#:9B(7\$!B(<-5487A(5-\$5!I!%GV J ; I)!+8, +>+-(57!</p> <p>%GV J ; I)!%\$ 0 A4<5!64A4<5!B484#:+@:(Q+8)! </p> <p>C<A\$A-&:!A\$A-+647\$!Y!%CDDY)!+8, +>+-(57!%CDDY+)!%=:64<5!7+-4<</p> <p>\$!7404<5!:+84#:+A+8)! </p> <p>G9:@ (8&:95\$47!%#:+A+Q+6\$S!#:+0 \$A+5+6\$S!#:+B4Q+6\$)! </p> <p>V:+4Q(8\$! </p> <p>" B45>(7\$! </p> <p>3879:+8!</p> <p>L5:+7-4-!</p>
H	a	a	<p>J\$=(-, &5(0+8\$!% ? +-, !(5! ? +-, (9-!:+(-, &5(8+8\$)! </p> <p>L54:!B(8-54B\$A-+=\$7! </p> <p>/ (5 0 (84:!5\$A:4B\$ 0 \$8-!-, \$54A&!% / F ;)!@ (5! 0 \$8(A497\$! </p> <p>L-, \$5!, (5 0 (84:!5\$#+ 0 \$7! </p> <p>" 5(0 4-47\$!+8, +>+-(57!%4847-5(Q(:\$X!:\$-5(Q(:\$)! </p> <p>G\$:\$B-+=\$!\$7-5(#\$8!5\$B\$A-(5! 0 (69:4-(57!%GPF 2 7)! </p> <p>!!</p>
C	a	-a	<p>/ &A8(-+B7!%Q(:A+6\$ 0 \$!Q(A+B:(8\$S!\$7Q(A+B:(8\$S!54 0 \$:-\$(8)! </p> <p>G\$:\$B-+=\$!\$7\$(- (8+8!5\$9A-4. \$5!+8, +>+-(57!%GGF37)!%@:9(0\$-+8\$S!</p> <p>%6\$7)=\$8:4@40+8\$S!\$7\$5-54:+8\$S!%\$7)B+-4:(A54 0 \$!=(5+ (0\$-+8\$S!</p> <p>@:9=(04 0+8\$)! </p> <p>L-, \$5!48+6\$A5\$7748-7!486!, 9 0 (5!7-4>+:+Q\$57!%>9A5(A+(8\$!</p> <p>-(A+54 0 4-\$S!-54Q(6(8\$S!4 0 +<!(9!8(5-5+A-:+8\$S!-(A+54 0 4-\$S!</p> <p>(0B45>4 0 4Q\$A+8\$)! </p> <p>1 \$8Q(6+4Q\$A+8\$7!%J(54<5!>5(0 4<5!6+4<5!B:(84Q\$A4 0 X!4:A54<5!</p> <p>0+64Q(:4 0)! </p> <p>" -&A+B4:!48+7A7&B, (-+B7!%(:48Q4A+8\$S!Z9\$-+4A+8\$S!5+7A5\$+6(8\$S!</p> <p>B:(Q4A+8\$S!45+A+54Q(:\$)! </p> <p>E\$8-54:!8\$5=(97!7&7-\$ 0 !%E [G)!7+0 9:48-7!% 0 \$-, &:@\$8+64-\$S!</p> <p>:+76\$04 0 @-\$4 0+8\$S! 0 (64@+8+:)! </p>
O			!
S			<p>L 0 \$#4<\!%]!\#'64&)! </p> <p>H+4 0+84!C!%]!W\$^^^+9'64&)! </p> <p>R+8B!%]!W_ 0 # '64&)! </p> <p>H+4 0+8!E!%]!_ ^^ 0 # '64&)! </p>

	2 9:-+=+4 0+87!
Vaccine	!
	1 EV!%:+@ \$-+0 \$)! 38@:9\$8Q4!%+8! I^ I^)! D8\$9 0 (B(BB4:!W\!(5! I\!%7+8B\$! I^W`)!
Lifestyle	!
	E955\$8-!7 0 (. +8#!%]! I!A4B . 7' ? \$\$. !486!]!W^!A4B . <&\$45)! F\$#9:45!A , &7+B4:!4B-+=+&!%]!W_ ^ 0+8' ? \$\$. \$! 0 (6\$54-\$<-(< =+#(5(97\$!]!\! 2 P ; 7\$!@ (5!]!W&)!
Clinical characterization	P (/) T a a a (a) D a (a)!
U	a\$=\$5!! ba\$=\$5+7 , c! / \$464B , \$! G , (5-8\$77! (@!>5\$4- , ! " 8(7 0+4! " # \$97+4! ! , &A\$5# \$97+4! ! 6&7# \$97+4!! C+Q+8\$77! * \$4 . 8\$77! a4-+#9\$! / &A(5\$0+4! ! 48(5\$0+4! ; , (54B+B!A4+8! J (? \$5!>4B . !A4+8! C5&!\$&\$7! ! 65&! 0 (9- , !'7 . +8!:\$7+(87!! 1 5\$47-!A4+8!
U a a	[474:!B(8#\$7+-(8!(5!5 , +8(55 , \$4! C5&!B(9# , ! bG+897++7c!%7\$: @<5\$A(5-\$6!A\$5B\$A+-(8)! bG(5\$!- , 5(4-c!%7\$: @<5\$A(5-\$6!A\$5B\$A+-(8)!
D -	2 &4:#+4! " 5- , 54:#+4! d AA\$5!>4B . !A4+8! E (8\98B-+=4: ! , &A\$5\$ 0 +4! D5\$<(5>+4: !A4+8!
Ga a (GI)	C+455 , \$4! [497\$47! H(0 +8#! " >6(0+84: ! (5!A\$: =+B!A4+8!
C a	" 8(7 0+4< " # \$97+4! 6(0+848B\$X! (5! C\$8#9\$<: +. \$!7& 0 A-(0 4- (: (#&! ' !B: +8+B4: !A5\$7\$8-4+-(8X! (5! d F ; 3<: +. \$!7& 0 A-(0 4- (: (#&! ' !B: +8+B4: !A5\$7\$8-4+-(8X! (5! V3!+8@ \$B+-(8<: +. \$!7& 0 A-(0 4- (: (#&! ' !B: +8+B4: !A5\$7\$8-4+-(8X! (5! 2 +0\$6X! (5! d 87A\$B+@+BX! (5! " 7& 0 A-(0 4+ B! !
Treatment	!
(" Q+- , 5(0 &B+8!_ ^^ 0 # '64&!@ (5! ^ _!64&7!K)!!	/ &65(0&B , : (5(Z9+8\$!Y^^ 0 # '64&!@ (5!^ _!64&7\$! (5! [+4Q(048+6\$!_ ^^ 0 #! 1 3C!@ (5!^ e!64&7\$! (5! 3=\$5 0 \$B+8!^ f I 0 # ' . # '64&!@ (5!^ \!64&7! K'<!! GA+5(8(:4B-(8\$!W^^ 0 #! 1 3C!@ (5!W_!64&7\$! (5!! C9-47-\$5+6\$!^ f _ 0 # '64&!98-+:!B95\$!

A (a	a a)	a	U4!@4B-(5!+8,+>+-(57! * 45@45+8! P8(O4A45+8! " B\$-&:74:+B&:+B!4B+6!% " G ")! V:9B(B(5→B(+67!% 0 \$- ,&:A5\$68+7(: (8\$\$!6\$04 0 \$- ,47(8\$\$! A5\$68+7(8\$\$!A5\$68+7(: (8\$)! 15(0 , \$0+8\$! [<4B\$-&:B&7-\$+8\$! E(:B , +B+8\$! H+4 0 +8!E!%466++(84:!6(7\$\$!+@!4:5\$46&!986\$5!97\$)! R+8B!%466++(84:!6(7\$\$!+@!4:5\$46&!986\$5!97\$)! H+4 0 +8!C!%466++(84:!6(7\$\$!+@!4:5\$46&!986\$5!97\$)! !
Outcomes (Day 0 = beginning of treatment)			!
WHO COVID O O (S a 1-5)	a		C4&!^! C4&!`! C4&!WY! C4&!\\^! C4&!e^!
L a ; 100 = a)	a (0-100; 0 =	a	C4&!^! C4&!\\! C4&!`! C4&!WY! C4&!\\^!
S (0-100;0 = ; 100 =)	a		C4&!<^!-(!<Y! C4&!<\\!-(!<W! C4&!^! C4&!W! C4&!I! C4&!\\! C4&!`! C4&!WY! C4&!IW! C4&!\\^! C4&!e^!
T a CT a (% a)			C4&!^! C4&!`! C4&!WY! C4&!\\^! !
Disease progression outcomes			!
			1 5\$7B+4!ELH3C<WT!F\$7A+54-(5&!G\$=\$5+-&!GB4:\$!%^<Y)! / (7A+4:+Q4+(8! 38-\$87+=E45\$!d 8+!%3E d)! 2 \$B , 48+B4:!= \$8+:4+(8! [(5465\$84:+8\$'6(A4 0 +8\$! C\$4- ,!

Ta 6 15 a a a a a a a a a a
(-HA, HA a HA-), a a a a a . Ta 2 5
a a a a a , Ta 6 8 COVID-19
a , Ta 9 a 10 a a a
COVID-19, a Ta 11 15 COVID-19 a .

Patients characteri ation

I a , 270 a COVID-19 . O , 195, 67,
a -HA, HA, a HA- . T a a
a a a a a a .
Ba a a a Ta 2. HA a a
, , a a a -HA.

!

Ta 2. Ba a a .						
Baseline characteristics	Overall females (n = 270)	Non-HA females (n = 195)	HA females (n = 67)	Spirolactone Users (n = 8)	Non-spiro (non-HA + HA) (n = 262)	p-value (overall)
Age (y/o)!)!	40.5 ± 11.5!	42.5 ± 11.6)	35.2 ± 9.5)	37.0 ± 7.1)	40.6 ± 11.5 !	"!#\$###%!
Height (m))	1.63 ± 0.06!					

Ta 3. C

Comorbidities	Overall females (n = 270)	Non-HA females (n = 195)	HA females (n = 67)	Spirolactone Users (n = 8)	Non-spiro (non-HA + HA) (n = 262)	p-value (overall)
Hypertension!	38 (14.1%)!	24 (12.3%)	12 (17.9%)	2 (25.0%)	'&!+% '\$2 - .!	#&2!+/03.!
Myocardial infarction	1 (0.4%)!	1 (0.5%)!		0	%!+#\$) - .!	#\$, ,!+/03.!
Stroke	1 (0.4%)!	1 (0.5%)		0	%!+#\$) - .!	#\$, ,!+/03.!
Chronic Heart Failure (CHD)	0!	0			#!	/01!
Lipid disorders	63 (23.3%)!	43 (22.1%)	17 (25.4%)	3 (37.5%)	&#!+((\$, - .!	#\$4 (!+/03.!
Type 2 diabetes mellitus ! (T2DM)	20 (7.4%)!	10 (5.1%)	8 (11.9%)	0	%2!+&\$, - .!	#\$)2!+/03.!
Pre-diabetes	21 (7.8%)!	11 (5.6%)	9 (13.4%)	2 (25.0%)	(#!+4\$& - .!	#&(!+/03.
Dysglycemia ! (T2DM + pre-diabetes)!	41 (15.3%)!	21 (10.8%)	17 (25.4%)	1 (12.5%)	'2!+%)\$* - .!	#\$4, !+/03.
Obesity	52 (19.3%)!	32 (16.4%)	18 (26.8%)	2 (25.0%)	*#!+%, \$% - .!	#\$) (!+/03.
Asthma	16 (5.9%)!	12 (6.2%)	4 (6.0%)	0	%&!+&\$% - .!	#\$,)!+/03.
Major depression	15 (5.6%)!	11 (5.6%)	4 (6.0%)	0	%*!+*\$4 - .!	#\$, &!+/03.
Anxiety-related disorders	41 (15.2%)!	22 (11.3%)	16 (23.9%)	3 (37.5%)	'2!+%)\$* - .!	#\$\$4!+/03.
Attention deficiency and hyperactive disorders (ADHD)	14 (5.2%)!	18 (9.4%)	7 (10.4%)	1 (12.5%)	% ' !+*\$# - .!	#&'!+/03.
Insomnia	15 (5.6%)!	8 (4.1%)	6 (9.0%)	1 (12.5%)	%)!+*\$' - .!	#\$4, !+/03.
Hypothyroidism	54 (20.0%)!	38 (19.5%)	14 (20.9%)	2 (25.0%)	*(!+%, \$2 - .!	#\$, &!+/03.
Autoimmune disorders	10 (3.7%)	9(4.6%)	1 (1.5%)	0	%#!+' \$2 - .!	#\$ ' 2!+/03.!
Menopause	65 (24.1%)!	56 (28.7%)*	8 (11.9%)	1 (12.5%)	&)!+()\$) - .!	#\$\$#!+/03.
Endometriosis	29 (10.4%)!	17 (8.7%)	11 (16.4%)	1 (12.5%)	(2!+*\$4 - .!	#&(!+/03.
Breast cancer	Y!%Wf_g)!	3 (1.5%)	1 (1.5%)	0)!+*\$* - .!	#\$, ,!+/03.!

HA = a c; / = - ca ; /a = -a cab
* =0.04 HA a

Ta 4 a a a a a . M
a a a a a HA a -HA
a . N a , a a a , a a
a . Wa a , a
a a a . T a a a a

BCG, a a a a , a a a
a a (Ta 5).

Ta 4. M a .

Current medications	Overall females (n = 270)	Non-HA females (n = 195)	HA females (n = 67)	Spirolactone Users (n = 8)	Non-spiro (non-HA + HA) (n = 262)	p-value (overall)
Beta-blocker	3 (1.1%)	3 (1.5%)	0	0	'!+%\$\$ - .!	5!#\$, !+/03.!
Angiotensin converter inhibitors (ACEi)	8 (3.0%)	5 (2.6%)	2 (3.0%)	1 (12.5%)	4!+(\$4 - .!	5!#\$, !+/03.!
Angiotensin-2 receptor blockers (ARB)	32 (11.8%)	19 (9.7%)	12 (17.9%)	1 (12.5%)	'%!+%\$\$2 - .!	#\$\$&%!+/03.!
Loop diuretics	3 (1.1%)	2 (1.0%)	0	1 (12.5%)	(!+#\$2 - .!	/01!
Thiazide diuretics	10 (3.7%)	8 (4.1%)	2(3.0%)	0	%#!+'\$2 - .!	5!#\$, !+/03.!
Calcium channel blockers (CCB)	16 (5.9%)	10 (5.1%)	6 (8.9%)	0	%&!+&\$% - .!	#\$2&!+/03.!
	!				!	
Statins!	51 (18.9%)	33 (16.9%)	17 (25.4%)	1 (12.5%)	*#!+%,\$% - .!	#\$*&!+/03.
Aspirin	1 (0.4%)	1 (0.5%)			%!+#\$) - .!	/01

Combined therapy (E+P) (for menopause)	29 (10.7%)	24 (12.3%)	5 (7.5%)	0	(, !+%%\$% - .!	#\$4 ' !+ /03.!
Oral contraceptives	36 (13.3%)	17 (8.7%)*	19 (28.4%)	0	' &!+% '\$4 - .!	##\$)*!
Other hormonal regimens	0	0	0	0	#!	/01!
Aromatase inhibitors (anastrozole; letrozole) or Selective estrogen receptor modulators (SERMs)	3 (1.1%)	1 (0.5%)	2 (3.0%)	0	' !+%\$% - .!	#\$2*!+ /03.!
Hypnotics	19 (7.0%)	10 (5.1%)	8 (11.9%)	1 (12.5%)	%2!+&\$, - .!	#\$&2!+ /03.!
Selective serotonin reuptaker inhibitors (SSRIs)	43 (15.9%)	27 (13.8%)	13 (19.4%)	3 (37.5%))#!+%%*\$' - .!	#\$44!+ /03.!
Other antidepressants and humor stabilizers	27 (10.0%)	15 (7.7%)	11 (16.4%)	1 (12.5%)	(&!+%##\$# - .!	#\$*4!+ /03.!
Benzodiazepines	3 (1.1%)	2 (1.0%)	1 (1.4%)	0	' !+%\$% - .!	#\$, , !+ /03.!
Atypical antipsychotics	7 (2.6%)	4 (2.0%)	3 (4.5%)	0	4!+(\$4 - .!	#\$, %!+ /03.!
Central nervo						

!!
!!
!!
!!
!!
!!

;4>:\$!ef!E:+8B4:!B:97-\$5+8#!!

!!

d F; 3!i!dAA\$5!\$7A+54-(5&!-54B-!+8@ \$B-+(8X!V3!i!V47-5(+8-\$7-+84:X!HA = a c; / = -

ca

!

!

Ta 7 a a a , a a
a , a - -a a a . P a a (71.1%) a
a a (67.0%) a a a (48.1%). S 20% 40% COVID-19
a a a (37.4%), (36.3%), (34.1%), a a
a (34.1%), a (33.3%), a (29.5%), a
(27.8%), a a (24.8%), a a (24.1%) a (21.5%). S

a 20% a a (15.9%), - a a (12.6%), a a a (10.4%), a a (8.1%), a a (8.1%), a a (7.8%), a a (7.7%), (6.7%), a (5.9%), a a (5.2%), a - a a (3.5%), (2.2%) a (1.1%).

COVID-19 a , a a : 1. Ea (< 2.0 a ; a): (1.0 ± 0.2), *abdominal pain* (1.1 ± 0.3); a a (1.1 ± 0.5), a a (1.2 ± 0.5), a a (1.2 ± 0.5), *dry cough* (1.2 ± 0.5), a a (1.2 ± 0.4), a a (1.3 ± 0.5), a (1.3 ± 0.5), (1.3 ± 0.5), a (1.3 ± 0.5), a (1.4 ± 0.7), - a a (1.4 ± 0.6), *sore throat* (1.4 ± 0.7), (1.5 ± 0.6), (1.5 ± 0.6), a a a (1.5 ± 0.6) and *diarrhea* (1.5 ± 0.8); a 2. La (> 2.0 a) *upper back pain* (2.0 ± 0.8); *lower back pain* (2.1 ± 0.7); a a (2.5 ± 1.0); a a (3.4 ± 1.3), a a (3.4 ± 1.3), a (3.8 ± 1.2).

D a COVID-19 a a a , (1.9 ± 1.0), a a a (1.8 ± 0.7), a a (1.7 ± 0.9), (2.3 ± 0.8); (2.4 ± 1.2), a (2.5 ± 1.6), a (2.7 ± 1.4) a - a a (2.8 ± 1.3); a a (3 5 a), a a a (3.0 ± 2.4), a a (3.2 ± 1.5), a a (3.3 ± 1.4), a a (3.3 ± 1.5), a a a (3.6 ± 1.8), a a (4.3 ± 2.1), a a (4.7 ± 2.5), a (4.8 ± 2.8), a a a (4.9 ± 2.6); a a (> 5 a), (5.4 ± 3.5) a (5.5 ± 1.9), a a (5.7 ± 3.5), (6.0 ± 2.6), *dry eyes* (6.2 ± 2.1), a a (7.0 ± 5.7), *dry mouth* (7.0 ± 0.0), a (7.2 ± 4.9) and a a (7.9 ± 6.2).

S a - -a a a a : , , a a a, a a , a , , a , , a a , a a , a a , a a , - a a , a a . A a a a a HA a -HA a (a), a a a a .

A a a a a a a . F -HA
a HA a a a a, a, , a , a a
a. A a, a a a a -HA a HA.
T - -a a a -HA a a .

! !
; 4>: \$!` f!E: +8+ B4: ! 0 48+ @ \$7-4-+ (87!+8!ELH3C<WTj!A5\$7\$8B\$!% g)\$!-+ 0 \$<- (<4AA\$4548B\$!486!6954-+ (8f!!

Clinical manifestations	Overall females (n = 270)	Non-HA females (n = 195)	HA females (n = 67)	Spirolactone Users (n = 8)	Non-spiro (non-HA + HA) (n = 262)	p-value! (overall)
Fever	!				!	!
D5\$7\$8B\$!% g))!	!	(n/s (p=0.32) vs HA) (n/s (p=0.64) vs spiro)	(n/s(p=0.41) vs spiro)	0 (n/s(p=0.57) vs no-spiro)	31 (11.8%)	0.52
; + 0 \$!-(! 4AA\$4548B\$!%64&7))!	± !	± (n/s (p=0.19) vs HA) (n/a vs spiro)	± (n/a vs spiro)	- (n/a)	1.5 ±	/a
C954-+(8!%64&7))!	± !	± (n/s (p=0.48) vs HA) (n/a vs spiro)	± (n/a vs spiro)	- (n/a)	(\$(!± !	/01!
“Feverish”	!				!	!
D5\$7\$8B\$!% g))!	!	(n/s (p=0.12) vs HA) (n/s (p=0.38) vs spiro)	(n/s(p=0.13) vs spiro)	0 ((n/s(p=0.26) vs no-spiro)	&%!+('\$' - .!	#\$%&!
; + 0 \$!-(! 4AA\$4548B\$!%64&7))!	± !	± (n/s (p=0.87) vs HA) (n/a vs spiro)	± (n/a vs spiro)	0 (n/a vs no-spiro)	%\$)!± !	/01!
C954-+(8!%64&7))!	± !	± (n/s (p=0.76) vs HA) (n/a vs spiro)	± (n/a vs spiro)	0 (n/a vs no-spiro)	(\$)!± !	/01!
Nasal congestion or rhinorrhea	!				!	!
D5\$7\$8B\$!% g))!	!	(n/s (p=0.33) vs HA) (n/s (p=0.73) vs spiro)	(n/s(p=0.48) vs spiro)	((n/s(p=0.65) vs no-spiro)	, #!+ ')\$* - .!	#\$*&!
; + 0 \$!-(! 4AA\$4548B\$!%64&7))!	± !	± (n/s (p=0.69) vs HA) (n/a vs spiro)	± ((n/a vs spiro)	± (n/a vs no- spiro)	± !	/01!
C954-+(8!%64&7))!	± !	± (n/s (p=0.72) vs HA) (n/a vs spiro)	± (n/a vs spiro)	± (n/a vs no-spiro)	' \$&!± !	/01!
Headache	!				!	!
D5\$7\$8B\$!% g))!	!	(n/s (p=0.12) vs HA) (n/s (p=0.33) vs spiro)	(n/s(p=0.13) vs spiro)	((n/s(p=0.15) vs no-spiro)	%(2!+)2\$2 - .!	#\$%&!
; + 0 \$!-(! 4AA\$4548B\$!%64&7))!	± !	± (n/s (p=0.10) vs HA) (n/a vs spiro)	± (n/a vs spiro)	± (n/a vs no-spiro)	%\$(!± !	/01!
C954-+(8!%64&7)	± !	±	±	±	*\$2!± !	/01!

		(n/s (p=0.63) vs HA (n/a vs spiro)	(n/a vs spiro)	(n/a vs no-spiro)		
Shortness of breath						
D5\$7\$8B\$!(g)		(n/s (p=0.72) vs HA (n/s (p=0.64) vs spiro)	(n/s(p=0.68) vs spiro)	((n/s(p=0.79) vs no-spiro)	%&!+&\$% - .!	#\$2*!
;+0\$!-(4AA\$4548B\$!(64&7)	± !	± (n/s (p=0.28) vs HA (n/a vs no-spiro)	± (n/a vs spiro)	(n/a vs no-spiro)	'\$4 ± !!	/01!
C954+-(8!(64&7)	± !	± (n/s (p=0.72) vs HA (n/a vs spiro)	± (n/a vs spiro)	(n/a vs no-spiro)	(\$* ± !	/01!
Anosmia						
D5\$7\$8B\$!(g)		(p = 0.025 vs HA (p = 0.0008 vs spiro)	(p = 0.0007 vs AGA-5ARi)	(p = 0.0036 vs no-5ARi)	%,% !+4(\$, - .!	####!
;+0\$!-(4AA\$4548B\$!(64&7)	± !	± (p=0.0009 vs HA (n/a vs spiro)	± (n/a vs spiro)	(n/a vs no-spiro)	'\$) ! ± !	"!####!
C954+-(8!(64&7)	± !	± (n/s(p=0.63) vs HA (n/a vs spiro)	± (n/a vs spiro)	3 (n/a vs no-spiro)	4\$, ! ± !	"!####!
Ageusia						
D5\$7\$8B\$!(g)		(p=0.015 vs HA (p=0.014 vs spiro)	(p=0.001 vs spiro)	(p=0.007 vs no-5ARi)	%2#!+&,\$4 - .!	####' !
;+0\$!-(4AA\$4548B\$!(64&7)	± !	± (p=0.011 vs HA (n/a vs spiro)	± (n/a vs spiro)	1 (n/a vs no-spiro)	'\$*! ± !	/01!
C954+-(8!(64&7)	± !	± (p=0.045 vs HA (n/a vs spiro)	± (n/a vs spiro)	(n/a vs no-spiro)	4\$%! ± !	/01!
Dry cough						

C954-+(8!%64&7)
)!

± !

±
(*p* = **0.037** vs *HA*)
(*n/a* vs *spiro*)

±
(*n/a* vs *spiro*)

(*n/a* vs *no-spiro*)

'\$' ± !

/01!

!						
D5\$7\$8B\$!(g)	!	<i>I</i> (<i>n/a</i> vs <i>HA</i>) (<i>n/a</i> vs <i>spiro</i>)	(<i>n/a</i> vs <i>spiro</i>)	(<i>n/a</i> vs <i>no-spiro</i>)	(!+##2 - . !	%%#!+ /03. !
; +0\$!-(!	\pm !	<i>I</i> (<i>n/a</i> vs <i>HA</i>) (<i>n/a</i> vs <i>spiro</i>)	3 (<i>n/a</i> vs <i>spiro</i>)	(<i>n/a</i> vs <i>no-spiro</i>)	+%6' . !	/01!
4AA\$4548B\$!(64&7)						
C954+-(8!(64&7)	\pm !	(<i>n/a</i> vs <i>HA</i>) (<i>n/a</i> vs <i>spiro</i>)	(<i>n/a</i> vs <i>spiro</i>)	(<i>n/a</i> vs <i>no-spiro</i>)	+%6' . !	/01!
Abdominal pain	!				!	!
!						
D5\$7\$8B\$!(g)	!	(<i>n/s</i> (<i>p</i> =0.52) vs <i>HA</i>) (<i>n/s</i> (<i>p</i> =0.75) vs <i>spiro</i>)	(<i>n/s</i> (<i>p</i> =0.58) vs <i>spiro</i>)	(<i>n/s</i> (<i>p</i> =0.70) vs <i>no-spiro</i>)	(!+2\$# - . !	##\$4*!
; +0\$!-(!	\pm !	\pm (<i>n/s</i> (<i>p</i> =1.0) vs <i>HA</i>) (<i>n/a</i> vs <i>spiro</i>)	\pm (<i>n/a</i> vs <i>spiro</i>)	(<i>n/a</i> vs <i>no-spiro</i>)	%%\$ \pm !	/01!
4AA\$4548B\$!(64&7)						
C954+-(8!(64&7)	\pm !	\pm (<i>n/s</i> (<i>p</i> =0.23) vs <i>HA</i>) (<i>n/a</i> vs <i>spiro</i>)	\pm (<i>n/a</i> vs <i>spiro</i>)	(<i>n/a</i> vs <i>no-spiro</i>)	2\$ \pm !	/01!
Conjunctival hyperemia	!				!	!
!						
D5\$7\$8B\$!(g)	!	(<i>n/s</i> (<i>p</i> =0.071) vs <i>HA</i>) (<i>n/s</i> (<i>p</i> =0.82) vs <i>spiro</i>)	(<i>n/s</i> (<i>p</i> =0.37) vs <i>spiro</i>)	(<i>n/s</i> (<i>p</i> =0.69) vs <i>no-spiro</i>)	((!+2\$) - . !	##\$%2!
; +0\$!-(!	\pm !	\pm (<i>n/s</i> (<i>p</i> =0.88) vs <i>HA</i>) (<i>n/a</i> vs <i>spiro</i>)	\pm (<i>n/a</i> vs <i>spiro</i>)	(<i>n/a</i> vs <i>no-spiro</i>)	%%\$ \pm !	/01!
4AA\$4548B\$!(64&7)						
C954+-(8!(64&7)	\pm !	\pm (<i>n/s</i> (<i>p</i> =0.54) vs <i>HA</i>) (<i>n/a</i> vs <i>spiro</i>)	\pm (<i>n/a</i> vs <i>spiro</i>)	(<i>n/a</i> vs vs <i>no-spiro</i>)	*\$# \pm !	/01!
Pre-orbital pain	!				!	!
!						
D5\$7\$8B\$!(g)	!	(<i>n/s</i> (<i>p</i> =0.57) vs <i>HA</i>) (<i>n/s</i> (<i>p</i> =0.57) vs <i>spiro</i>)	(<i>n/s</i> (<i>p</i> =0.78) vs <i>spiro</i>)	(<i>n/s</i> (<i>p</i> =0.53) vs <i>no-spiro</i>)	') !+%' '\$# - . !	##\$4#!+ /03. !
; +0\$!-(!	\pm !	\pm (<i>n/s</i> (<i>p</i> =0.27) vs <i>HA</i>) (<i>n/a</i> vs <i>spiro</i>)	\pm (<i>n/a</i> vs <i>spiro</i>)	(<i>n/a</i> vs <i>no-spiro</i>)	%) \pm !	/01!
4AA\$4548B\$!(64&7)						
C954+-(8!(64&7)	\pm !	\pm (<i>p</i> =0.016) vs <i>HA</i>) (<i>n/a</i> vs <i>spiro</i>)	\pm (<i>n/a</i> vs <i>spiro</i>)	(<i>n/a</i> vs <i>no-spiro</i>)	(2\$ \pm !	/01!
Dry eyes	!				!	!
!						
D5\$7\$8B\$!(g)	!	(<i>n/s</i> (<i>p</i> =0.99) vs <i>HA</i>) (<i>n/s</i> vs <i>spiro</i>)	(<i>n/s</i> vs <i>spiro</i>)	(<i>n/s</i> vs <i>no-spiro</i>)	&!+(\$' - . !	##\$, 2!+ /03. !
; +0\$!-(!	\pm !	\pm (<i>n/a</i> vs <i>HA</i>) (<i>n/a</i> vs <i>spiro</i>)	(<i>n/a</i> vs <i>spiro</i>)	(<i>n/a</i> vs <i>no-spiro</i>)	%) \pm !	/01!
4AA\$4548B\$!(64&7)						

COVID-19 course and outcomes

Ta 10 a a - - a a a a a a

COVID-19 a a . T - - a , PCR, a a

a a a a a a a a HA-

a -HA, HA, a a - , HA- a

a a . C , - - a a a , a

a -HA a HA.

Ta 11 a a COVID-19. A a

a a HA , a a a a

a -HA a a . C ,

, a a HA a -

HA, a HA a HA- Da 2 7, a

a a a a . HA- a

a - a Da -3 -1 a Da 7, a a a HA a

Da -3 -1 a Da 2 7.

;4>:.\$!W^f!ELH3C<WT!B:+8+B4:!(9-B(0\$7f

Clinical clustering	Overall females (n = 270)	Non-HA females (n = 195)	HA females (n = 67)	Spirolactone Users (n = 8)	Non-spiro (non-HA + HA) (n = 262)	p-value (overall)
Time-to-treat!	3.0 ± 1.8	3.0 ± 1.9 (n/s (p=0.11) vs HA) (p<0.007 vs spiro)	3.4 ± 1.4 (p=0.0001 vs spiro)	0.5 ± 1.1 (Median = 0; 95%CI = 0.7) (p=0.0003 vs no-spiro) (p = 0.0028 vs no-spiro after adjustment for symptomatic patients only)	3.1 ± 1.8	#####!
Duration of positive rtPCR (days)!	13.9 ± 6.1	13.5 ± 5.7 (p=0.033 vs HA) (p=0.025 vs spiro)	15.7 ± 6.7 (p=0.0005 vs spiro))	8.7 ± 3.0 (p=0.015 vs no-spiro) (p = 0.015 vs no-spiro after adjustment for symptomatic patients only)	%)\$#!± 6.1!	##\$*4!
Remission not including anosmia (days)!	5.8 ± 4.7	5.5 ± 4.7 (p=0.0003 vs HA) (p=0.0008 vs spiro) (p = 0.015 vs spiro after adjustment for symptomatic patients only)	7.2 ± 4.5 (p<0.0001 vs spiro)) (p=0.0002 vs spiro after adjustment for only symptomatic patients)	1.4 ± 1.4 (Median = 1; 95%CI = 1.0) (p=0.0003 vs no-spiro) (p = 0.0046 vs no-spiro after adjustment for symptomatic patients only)	&\$#!± 4.7!	"!##\$###! (p < 0.0001 after adjustment for only symptomatic patients)!
Remission including anosmia (days)!	9.6 ± 7.3	9.0 ± 7.1 (p=0.0001 vs HA) (p=0.0004 vs spiro) (p=0.0046 vs spiro after adjustment for symptomatic patients only)	12.4 ± 7.0 (p<0.0001 vs spiro)) (p<0.0001 vs spiro after adjustment for only symptomatic patients)	1.7 ± 2.0 (Median = 1; 95%CI = 0.3) (p=0.0001 vs no-spiro) (p = 0.0013 vs no-spiro after adjustment for symptomatic patients only)	,\$,!± 7.3!	"!##\$###! (<0.0001 after adjustment for only symptomatic patients)!

HA = a c; / = - ca ; /a = -a cab

Ta 11. COVID-19 .

Clinical evolution	Overall females (n = 270)	Non-HA females (n = 195)	HA females (n = 67)	Spiro lactone Users (n = 8)	Non-spiro (non-HA + HA) (n = 262)	p-value (overall)
Days -7 to -4!	\pm	\pm	\pm	\pm	4, \$&! \pm	# \$ ' *!+ /03.!
!	!	(n/s (p=0.41) vs HA) (n/s (p=0.21) vs spiro)	(n/s (p=0.34) vs spiro)	(n/s (p=0.23) vs no-spiro)	!	
Days -3 to -1!	\pm	\pm	\pm	\pm	' (\$, ! \pm	# \$ # %)!
!	!	(n/s (p=0.41) vs AGA vs HA) (p=0.007 vs spiro)	(p=0.003 vs spiro)	(p=0.005 vs no-spiro)	!	
Day 0!	\pm	\pm	\pm	\pm	' % \$ (! \pm	# \$ # 4 (!+ /03.!
!	!	((p=0.045) vs AGA vs HA) (n/s (p=0.29) vs spiro)	(n/s (p=0.16) vs spiro)	(n/s (p=0.25) vs no-spiro)	!	
Day 1!	\pm	\pm	\pm	\pm	\pm	# \$ # # # 2!
!	!	(p=0.0002 vs HA) (n/s (p<0.30) vs spiro)	(p=0.12) vs spiro (n/s)	(n/s (p=0.23) vs no-spiro)	!	
Day 2!	\pm	\pm	\pm	\pm	4) \$ 2! \pm	" ! # \$ # # # %!
!	!	(p<0.0001 vs HA) (p=0.0051) vs spiro)	(p=0.0007 vs spiro)	(p=0.044 vs no-spiro)	!	
Day 3!	\pm	\pm	\pm	\pm	\pm	" ! # \$ # # # %!
!	!	(p=0.0007 vs HA) (p<0.0001 vs spiro)	(p=0.0001 vs spiro)	(p=0.0016 vs no-spiro)	!	
Day 7!	\pm	\pm	\pm	\pm	, ' \$ 2! \pm	# \$ # % 2!
!	!	(p=0.023 vs HA) (n/s (p=0.15) vs spiro)	(p=0.023 vs spiro)	(n/s (p=0.094) vs no-spiro)	!	
Day 14!	\pm	\pm	\pm	\pm	, 2\$) ! \pm	# \$ & 4 !+ /03.!
!	!	(n/s (p=0.45) vs HA) (n/s (p=0.67) vs spiro)	(n/s (p=0.49) vs spiro)	(n/s (p=0.62) vs no-spiro)	!	
Day 21!	\pm	\pm	\pm	\pm	, , \$) ! \pm	% \$ # !+ /03.!
!	!	(n/s vs HA) (n/s vs spiro)	(n/s vs spiro)	(n/s vs no-spiro)	!	
Day 30!	\pm	\pm	\pm	\pm	, , \$ 2! \pm	% \$ # !+ /03.!
!	!	(n/s vs HA) (n/s vs spiro)	(n/s vs spiro)	(n/s vs no-spiro)	!	

Day 60!	\pm	\pm	\pm	\pm	###\$#! \pm	#\$#!+/03.!
		(n/s vs HA) (n/s vs spiro)	(n/s vs spiro)	(n/s vs no-spiro)		!
HA = a c; / = - ca ; /a = -a cab ; CI = c c a						
A Ta 12,			W H a O a a (WHO) COVID			
O a O			a , HA a a a			
a -HA a HA-			Da 0 a 7, a a a Da 14.			
N a a S 3 5			a .			
T a a			a a Ta 13.N			
a a a			a a . C , HA			
a			a -HA a HA- a			
(= 0.004 a 0.028,			a a a (Da 0).			
T a a			a (Da 3, 7, 14 a 30). E -HA			
(a a a), Da 3 a a			a Da 0.			
;4>:\$!WI. WHO COVID-19 O a O .						
WHO COVID Ordinal Outcomes	Overall females (n = 270)	Non-HA females (n = 195)	HA females (n = 67)	Spiro nolactone Users (n = 8)	Non-spiro (non-HA + HA) (n = 262)	p-value! (overall)
Day 0)!	!	(p=0.028 vs HA) (n/s((p=0.15) vs spiro)	(p=0.028 vs spiro)	(n/s((p=0.098) vs no-spiro)		0.002 !
G-4#\$!W	!				172 (65.6%)	
G-4#\$!I	!				90 (34.4%)	
G-4#\$7!\<_	!				#!	!
Day 7)!	!	(p=0.021 vs HA) (n/s vs spiro)	(p=0.015 vs spiro)	(n/s vs no-spiro)		0.021 !
G-4#\$!W	!				()4!+,)\$' - .!	!
G-4#\$!I	!				%*!+*\$4 - .!	!
G-4#\$7!\<_	!				#!	!
vs!C4&!^ %p-=4:9\$)!					"!#\$####!	!
Day 14)!	!	(n/s vs HA) (n/s vs spiro)	(n/s vs spiro)	(n/s vs no-spiro)		0.84 !
G-4#\$!W	!				(&#!+, ,\$(- .!	!
G-4#\$!I	!				(!+#\$2 - .!	!

G-4#7!\<_	!				#!	!
vs!C4&!^					"!#\$###%!	!
%p-=4:9\$)!						
vs!C4&!`					#\$(2!+/03.!)	!
%p-=4:9\$)!						
Days 30 and 60	!	(n/s vs HA) (n/s vs spiro)	(n/s vs spiro)	(n/s vs no-spiro)	!	!
)!						
G-4#\$!W	!				(&(!+%## - .!)	/01!
G-4#\$!I	!				#!	/01!
G-4#7!\<_	!				#!	/01!
HA = a c; / = - ca ; /a = -a cab ; / = - ca						
Ta 13. L	a	a	a	COVID-19.		
Loss of ability of everyday activities (%)	Overall females (n = 270)	Non-HA females (n = 195)	HA females (n = 67)	Spironolactone Users (n = 8)	Non-spiro (non-HA + HA) (n = 262)	p-value (overall)
Day 0!	±	±	±	(n/s (p=0.098) vs no-spiro)	, \$*!±	###!
	!	(p=0.004) vs HA (n/s (p=0.15) vs spiro)	vs spiro	(p=0.028)		!
Day 3!	±	±	±	(p=0.48) vs no-spiro	'\$(!±	#\$'#!+/03.!)
	!	(n/s (p=0.17) vs HA)) (n/s (p=0.57) vs spiro)	(n/s (p=0.30) vs spiro)			!
vs!C4&!^					#####%!	!
%p-=4:9\$)						
Day 7!	±	±	±	(n/s (p=0.78) vs no-spiro)	±	#\$2'!+/03.!)
	!	(n/s (p=0.95) vs HA) (n/s (p=0.82) vs spiro)	(n/s (p=0.68) vs spiro)			!
vs!C4&!^					"!#\$###%!	!
%p-=4:9\$)!						
vs!C4&!`					##\$*!+/03.!)	!
%p-=4:9\$)!						
Day 14!	±		±		±	#\$, ,!+/03.!)
	!	(n/s vs HA) (n/s vs spiro)	(n/s vs spiro)	(n/s vs no-spiro)		!
vs!C4&!^					"!#\$###%!	!
%p-=4:9\$)!						
vs!C4&!`					#\$, *!+/03.!)	!
%p-=4:9\$)!						

<div>%p=-4:9\$)! Day 30!</div>							<div>%%\$#!+ / 03.!</div>	

vs!C4&!^ %p=-4:9\$)!	!	!
vs!C4&!` %p=-4:9\$)!	!	!
vs!C4&!WY %p=-4:9\$)	!	!
HA = a c; / = - ca ; CI = c c a		

Disease progression outcomes	Overall females (n = 270)	Non-HA females (n = 195)	HA females (n = 67)	Spironolactone Users (n = 8)	p-value (overall)
Brescia COVID-19 Respiratory Severity Scale (0-4)	0 !	0	0	0	%###!+/03..!
Hospitalization	0!	0	0	0	%###!+/03..!
Mechanical ventilation	0!	0	0	0	%###!+/03..!
Noradrenaline/dopamine	0!	0	0	0	%###!+/03..!
Death	0!	0	0	0	%###!+/03..!

The importance of an early diagnosis of COVID-19

T a a a a a

a COVID-19. O a a

COVID-19 a , COVID-19

a , a a a . A

a a a , a a

a COVID-19. T a a a a
a a a .
R a a a a a a ,
a a a a a (a a
) . C a , a a , a a a
a . E a a , a a a a a
a a , a a a . M ,
a a a a a a a .
M a a - a a a a
, a a a a a
a , a a a a a a
a .
T a a a COVID-19 a
a a a COVID-19 a a
. W a a COVID-19 a a

The patient with COVID-19: characteri ation of the patients and the disease

Ba a a a -HA a HA
a a HA a a BMI. T
a a a a a
HA a . F , a HA (
a a a , a a a) a a a , a a
a a .
D BMI HA a -HA a a a
a , a a a . C ,
a , HA a a a
COVID-19 a -HA

W a a a
 , a a a HA a -HA a ,
 a PCOS a a

HA.

I a a a a a , a
 a (23-26). A a a
 a a a a 80% a . T a a-a a
 a , - , URTI- , a GI - a a
 a , a , a
 . T a a URTI- a a HA a a
 a a a a a .

T a a a , a a a
 a a a a a COVID-19 a
 a a a a a
 a . A , a a a a a a
 a a a a a SARS-C V-2, a
 a a - a , a a , a
versus .

C , a a a a a
 a a a a , a a a .
 T a a a , a Xa a a a a , a
 a a , COVID-19 a
 - a *per se*. V a D, a a , a a C,
 a a a . H , a a
 a .

COVID-19 outcomes

A a COVID-19 a , a PCR-
 SAR-C V-2 a a a a a
 HA- a -HA, HA, a a - . H , - -

a a a HA- a .H , a
a a COVID-19 a a
a , a COVID-19 a a HA-
a a -a a a .

U HA- , - - a a a a
-HA a HA a , a a a , a HA a
-HA, a a a a a HA a a a
a .

A a a a a a
, HA- a , a
- -a a a a a -HA a . T a a
a a a a a a .
I a a , a a a, a a a ,
a a a a HA a a a ,
a a a a a a AGA (5,6,14,16,17), a
TMPRSS-2.

D a Da 0 a 7 HA
a , a a
, a a (Ta 11 13),
a a HA a , a .
D HA, a a a
a a a a .

T a a a a a
a a a a a a 14 a , a
a a a - a a . A
HA a a -HA a HA- a ,
a a , a a a a .

U a a , a a
30 a a a a .H , a a a a a

a CT a a
a a .H , a a a a
a .

C a a COVID-19 , WHO COVID S a a
B a R a S a , a a a a ,
a a a , a a , a
I a , a .

O - a HA a , HA a a a
a a a COVID-19. A a , a
a COVID-19 a a a
 , a a a a . S a a
a COVID-19, a
a - -a a a 2 (ACE2) a , a
a (AT) 2- -AT1 a , a TMPRSS2 a , a a
a a a a - a a a (20-22), a
a a .

Post-COVID syndrome?

T a a a COVID-19
a a a , a a a , a a , a
- , - , a -COVID , a a
a a 20 30% a , a , a ,
a , a , a a a , a a ,
a (CFS), a a a
a a (27,28). H , a a a a
 , a a , a a a
a a a a .

The effect of specific treatments on COVID-19: comparison with existing literature

W a a a , a a , a a
a a a a , a
a , a a a (10-12). A a a
a , a
a - a , a a . H , a RCT a
a a a a a
 , a COVID-19 a .

Limitations

A a a a - a -
RCT, a a a a
a a , a a a a a a a
 , a a , , . A , a
a a a a . H , a
a - a COVID-19
a , a RCT a a a -
.

T a a a - a a
a a a COVID-19 a
a a a a a a , : 1. La a a
a a a a COVID-19 a a ; 2.
S - a COVID-19; 3. I a a -
COVID-19, ; a 4. C a
a , a a COVID-19
a . A a a a a , a
a a a , a .

Final discussion

S COVID-19 a , , a a a , a
a a a a a a a
a a a a , a a ,
a .
T a a a a a a a ,
, a a a a
COVID-19, a a .
A a , HA a a a COVID-19 ,
a a a a a
a -HA a a . T a a
a 100 HA a a , a
-HA. T a a a
a AGA a a a , .

Conclusion

A , a COVID-19 a a a a a
a a a a a , a a
, a a a a
a a a a a
a a a a COVID-19 ,
a a a a .
W a - a (-HA), HA a a a a
a a , COVID-19 a
a a a a . S a a a
a a HA.

F a

T a C a I
(B a a, DF, B a) a A B I (I , CA, USA).

C a
A a a a a

References

1. G a W, N Z, H Y, a . C a a a a a 2019
C a. *N Engl J Med* 2020; F 28.
2. Ha a a a K, K a S, N C, a . O a a
COVID-19: A a Ea Da a F N Y C [a a , 2020 Ma 29]. *Obesity (Silver Spring)*. 2020;10.1002/ .22923.
3. Ka M, S a F, M a EK, a . A a O D a
S a Pa COVID-19 [a a , 2020 A 30]. *Obesity (Silver Spring)*. 2020;10.1002/ .22859.
4. Pa a L, K DG, L W, a . S , a a a
a a a a - a , a
- a a , a a COVID-19 B ,
N Y [a a , 2020 Ma 16]. *Metabolism*. 2020;108:154262.
5. Ca a a AB, Za FG, R a RG, A LCP, V a VC, A A,
Da a LP, Ma a A, Ka a -D a L, L a T, J a DLM,
Ba E S a PGM, T a a L, A -S a EO, La a a LN, S a AT,
E LS, P a AJ, F a FGR, G a a OCE, Da a VCS, F a
RHM, M a EP, G NA, Ca FF, Ma a IS, H a F CR, K a
APM, A a a RB, B O a MF, S a-N A, Fa a a M, L

- RD, Ma a FR, B a O; C a C -19 B a I I a .
H A M - -M a C -
19. N E J M . 2020 J 23:NEJM a2019014. :
10.1056/NEJM a2019014.
6. Z F, Y T, D R, a . C a a a a a
a COVID-19 W a , C a: a [
a a , 2020 Ma 11] [a a La . 2020 Ma
12;:]. *Lancet*. 2020;S0140-6736(20)30566-3.
7. La SA, G a KH, B Q, a . T I a P C a D a
2019 (COVID-19) F P R C Ca : E a a
A a [a a , 2020 Ma 10]. *Ann Intern Med*.
2020;10.7326/M20-0504.
8. W C, C X, Ca Y, a . R Fa A a W A R a
D S a D a Pa W C a D a 2019 P a
W a , C a [a a , 2020 Ma 13]. *JAMA Intern Med*.
2020;10.1001/ a a .2020.0994.
9. W C, C X, Ca Y, a . R Fa A a W A R a
D S a D a Pa W C a D a 2019 P a
W a , C a [a a , 2020 Ma 13]. *JAMA Intern Med*.
2020;10.1001/ a a .2020.0994.
10. :// . . / a / a - a - a - a - / -19/ a a-
a (La a S 29 , 2020)
11. :// . . / a /2019- / / a - a -
a a - a . (La a S 29 , 2020)
12. S EK, Za a LD, A KN, a . C a D a 2019 Ca
S a -U S a , Ja a 22-Ma 30, 2020. *MMWR M M a W R*
2020; 69:759.
13. Ca a , F.A. R COVID-19: a
. *BMC Endocr Disord* **20**, 149 (2020). :// . /10.1186/ 12902-020-
00626-0
14. Pa a a G, S a A, P C, B F, D B R, C a F, S a a a S,
A FE. COVID-19 a a a a : a . J I M .
2020 A ;288(2):192-206. : 10.1111/ .13091.

15. G A, Va -Ga a S, Wa CG, a . A a a : a a a a COVID-19 a S a - A a a COVID-19 [a a , 2020 A 16]. *J Cosmet Dermatol*. 2020;10.1111/ .13443.
16. G A, M C J, Wa CG, a . W a a a a COVID-19? A a a a [a a , 2020 A 1]. *Dermatol Ther*. 2020; 13365.
17. M C J, Wa CG, H a S, Va -Ga S, G a F, C B, R R, S a -V a S, I a RM, Ta MA, Ca a FA, M a NA, S a J, S a R, G A. A R G Va a P COVID-19 D a S : A P L a S H a COVID-19 Ma Pa . J E A a D a V . 2020 S 25.
18. K a K, A MP, G TA, a . A a a C a D a 2019 (C -19) - a Da a , - a . C I D 2020.
19. G A, Wa CG, H a S, M C J, Va -Ga S, G a F, C B, R R, S a -V a S, Ra PM, Ca a FA, K a M, T A, S a J, S a R. A -a a a COVID-19 : a 77 a . J E A a D a V . 2020 S 25. : 10.1111/ .16953.
20. Ca a FA. Ca a COVID-19- a a ? A J P E M a . 2020 Ma 1;318(5):E587-E588. : 10.1152/a .00136.2020.
21. Ca a FA, Wa CG, G A. S a : A A -a a A - D T a Ma P P A a N C a (SARS-C V-2) I A R a D S (ARDS) COVID-19. F M (La a). 2020 J 28;7:453. : 10.3389/ .2020.00453.
22. Ca a FA, G A, Wa CG. S a a SARS-C V-2: Ta a , a 2 (ACE2), a -a -a (RAAS). M H . 2020 J 16;143:110112. : 10.1016/ . .2020.110112.
23. :// . a . / / a - a -2019- -19- a - a ? R =126981& = (La a S 29 , 2020)

